1241405-22-0

Basic information

• Product Name: (2-fluoro-4-methylphenyl)acetaldehyde
• Synonyms: (2-fluoro-4-methylphenyl)acetaldehyde
• CAS NO: 1241405-22-0
• Molecular Weight: 152.168
• Mol File: 1241405-22-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (2-fluoro-4-methylphenyl)acetaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: (2-fluoro-4-methylphenyl)acetaldehyde(1241405-22-0)
• EPA Substance Registry System: (2-fluoro-4-methylphenyl)acetaldehyde(1241405-22-0)

Safety Data

• Hazardous Substances Data: 1241405-22-0(Hazardous Substances Data)

Upstream product

• 4009-98-7 (methoxymethyl)triphenylphosphonium chloride 
• 146137-80-6 2-fluoro-4-methylbenzaldehyde 
• 452-80-2 2-fluoro-4-methylaniline 

Downstream Products

• 518070-28-5 2-(2-fluoro-4-methylphenyl)acetic acid 
• 1241405-26-4 methyl (2-fluoro-4-methylphenyl)acetate 
• 1241405-27-5 methyl 2-(2-fluoro-4-methylphenyl)propanoate 
• 1241405-31-1 methyl 2-[4-(bromomethyl)-2-fluorophenyl]propanoate 
• 1241405-35-5 methyl 2-(2-fluoro-4-[(1-methoxycarbonyl-2-oxocyclopentyl)methyl]phenyl)propanoate 
• 1241405-00-4 2-(2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl)propanoic acid 

Relevant articles and documents

Loxoprofen derivative

The invention provides a Loxoprofen derivative. Gastrointestinal tract side effects are low, and the bioavailability can be improved.

Properties and synthesis of 2-{2-fluoro (or bromo)-4-[(2-oxocyclopentyl) methyl]phenyl}propanoic acid: Nonsteroidal anti-inflammatory drugs with low membrane permeabilizing and gastric lesion-producing activities

We previously proposed that membrane permeabilization activity of NSAIDs is involved in NSAID-induced gastric lesions. We here synthesized derivatives of loxoprofen that have lower membrane permeabilization activity than other NSAIDs. Compared to loxoprofen, the derivatives 10a and 10b have lower membrane permeabilization activity and their oral administration produced fewer gastric lesions but showed an equivalent anti-inflammatory effect. These results suggest that 10a and 10b are likely to be therapeutically beneficial as safer NSAIDs.